Skip to main content

Table 1 Patients characteristics

From: How important is early magnetic resonance imaging of the temporomandibular joint for the treatment of children with juvenile idiopathic arthritis: a retrospective analysis

  Total cohort MRI cohort Statistics
  All With TMJ-Arthritis Without TMJ-Arthritis Comparison with/without TMJ-Arthritis
n = 147 n = 111 n = 91 n = 20  
Female (% of cohort) 88 (60%) 70 (63%) 60 (66%) 10 (50%) p = 0.2
JIA subtypes (% of cohort)      p = 0.007*
 Enthesitis related 19 (13%) 10 (9%) 4 (4%) 6 (30%)
 Oligoarticular 70 (48%) 49 (44%) 40 (44%) 9 (45%)
 Extended oligoarticular 16 (11%) 15 (14%) 15 (16%) 0
 Polyarticular RF neg 28 (19%) 26 (23%) 23 (25%) 3 (15%)
 Psoriatic 8 (5%) 7 (6%) 6 (7%) 1 (5%)
 Systemic 1 (0.7%) 1 (1%) 1 (1%) 0
 Undifferentiated 5 (3%) 3 (3%) 2 (2%) 1 (5%)
ANA pos (%) 60 (41%) 51 (46%) 46 (50%) 5 (25%) p = 0.04*
RF pos (%) 1 (0.7%) 1 (0.9%) 0 1  
HLA B27 pos/tested (%) 18/124 (15%) 12/97 (12%) 8/78 (10%) 4/19 (25%) p = 0.2
Uveitis (% of cohort) 7 (5%) 7 (8%) 6 (7%) 1 (5%) p = 0.7
Age at JIA diagnosis in years (mean; median) 7.3; 6.9 6.6; 6.0 6.3; 5.8 8.2; 8.4 p = 0.04*
JIA disease duration in years (mean; median) 2.0; 1.9 2.2; 2.3 2.3; 2.4 1.6; 1.6 p = 0.01*
Age at TMJ diagnosis in years (mean; median)    7.0; 6.4   
Time until TMJ diagnosis in years (mean; median)    0.7; 0.4   
Medication      
 NSAID (%) 126 (86%) 96 (86%) 79 (86%) 17 (85%)  
 Methotrexate (%) 47 (32%) 44 (40%) 37 (41%) 7 (35%)  
 Etanercept (%) 14 (10%) 14 (13%) 14 (15%) 0  
 Infliximab (%) 7 (5%) 6 (5%) 6 (7%) 0  
 Prednisone (%) 11 (7%) 9 (8%) 8 (9%) 1 (5%)  
 Sulfasalazine (%) 2 (14%) 1 (1%) 0 1 (5%)  
 Leflunomide (%) 3 (2%) 2 (2%) 2 (2%) 0  
 Adalimumab (%) 2 (1%) 2 (2%) 2 (2%) 0  
 Tocilizumab (%) 1 (0.5%) 1 (1%) 1 (1%) 0  
At least 1 DMARD (%) 48 (33%) 45 (41%) 38 (42%) 7 (35%)  
  1. *statistically significant (p-value <0.05).